Anti-Vascular Endothelial Growth Factor Therapeutics Market Size and Outlook 2030

Report Description

Forecast Period	2026-2030
Market Size (2024)	USD 14.38 Billion
CAGR (2025-2030)	3.65%
Fastest Growing Segment	Eylea
Largest Market	North America
Market Size (2030)	USD 17.83 Billion

Market Overview

The Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, valued at USD 14.38 Billion in 2024, is projected to experience a CAGR of 3.65% to reach USD 17.83 Billion by 2030. Anti-vascular endothelial growth factor (VEGF) therapeutics are a class of biological drugs designed to inhibit the formation of new blood vessels, a process crucial in the progression of various diseases. These therapies are predominantly utilized in the treatment of ophthalmic conditions, such as age-related macular degeneration and diabetic macular edema, as well as several types of cancer. The market's expansion is fundamentally driven by the increasing global prevalence of chronic diseases necessitating such interventions, ongoing advancements in drug formulations and delivery mechanisms, and the demographic shift towards an aging global population. According to the European Federation of Pharmaceutical Industries and Associations, in 2023, the pharmaceutical industry invested an estimated €50 billion in research and development within Europe, underscoring significant ongoing innovation across the broader pharmaceutical sector that includes anti-VEGF advancements.

Despite robust growth drivers, the global anti-VEGF therapeutics market faces a significant challenge stemming from the impending patent expirations of several key established drugs. This scenario is expected to intensify biosimilar competition, potentially leading to price erosion and impacting revenue generation for originator manufacturers, thereby impeding overall market expansion.

Key Market Drivers

The escalating global prevalence of ophthalmic diseases, particularly age-related macular degeneration (AMD) and diabetic macular edema (DME), serves as a substantial impetus for the anti-vascular endothelial growth factor therapeutics market. These debilitating conditions, which are leading causes of blindness and severe vision impairment worldwide, necessitate effective and sustained pharmacological intervention. Enhanced diagnostic capabilities and improved patient access to ophthalmological care contribute to a larger identified patient pool requiring treatment. For instance, according to a review published in *JAMA* in January 2024, age-related macular degeneration affects an estimated 196 million people worldwide. This demographic reality directly translates into a sustained and growing demand for anti-VEGF agents.

The continuous growth of the aging global population is another critical driver. As individuals advance in age, their susceptibility to chronic and degenerative eye conditions significantly increases, making older adults the primary demographic affected by conditions responsive to anti-VEGF treatment. This demographic shift intensifies the caseload for ophthalmologists and drives the prescription rates for these specialized therapeutics. According to the United Nations Department of Economic and Social Affairs, in its *World Population Ageing 2023* report, the number of old people in the world may rise from 761 million in 2021 to 1.6 billion in 2050. This burgeoning elderly demographic ensures a robust and expanding patient base for anti-VEGF therapies. Furthermore, the market reflects significant commercial activity, as evidenced by major pharmaceutical companies' performance; according to Regeneron Pharmaceuticals, in its second quarter 2024 financial and operating results, Eylea net sales in the United States were $1.53 billion for Eylea HD and Eylea combined.

Download Free Sample Report

Key Market Challenges

The global anti-vascular endothelial growth factor therapeutics market faces a significant challenge from the impending patent expirations of several established biological drugs. This scenario is expected to intensify biosimilar competition, which directly influences the market dynamics for originator manufacturers. As biosimilar versions become available, they enter the market at considerably lower prices to gain market share. This increased competition drives down the average selling prices across the entire product class.

This competitive pressure directly hampers the growth of the anti-VEGF therapeutics market by eroding the revenue streams for companies that developed the original, patented therapies. According to Medicines for Europe, in 2023, over 60% of biosimilar tender awards in Europe were based solely on price as the deciding criterion, demonstrating the acute focus on cost-effectiveness in procurement. This aggressive price-based competition compels originator manufacturers to reduce their product pricing to remain competitive, directly impacting their profitability and overall revenue generation within the market. This economic shift ultimately impedes the broader market expansion by reducing the financial returns for continued innovation in the sector.

Key Market Trends

The Global Anti-Vascular Endothelial Growth Factor (VEGF) Therapeutics Market is significantly shaped by the expanding market penetration of anti-VEGF biosimilars. This trend is driven by the imperative to enhance cost-effectiveness and broaden patient access to critical therapies, particularly as key originator biologics face patent expirations. Biosimilars introduce robust price competition, thereby fostering greater affordability and increasing the overall volume of anti-VEGF treatments dispensed. According to the Association for Accessible Medicines, biosimilars generated $12.4 billion in savings for the U. S. healthcare system in 2023 alone, demonstrating their substantial economic impact on healthcare expenditures. This competitive landscape compels market players to innovate while simultaneously making essential treatments more accessible across diverse patient populations.

Another pivotal trend influencing the market is the development of extended-duration anti-VEGF formulations. These advanced formulations aim to reduce the frequency of intravitreal injections, thereby alleviating patient burden and potentially improving adherence to treatment regimens for chronic ophthalmic conditions. Such innovations represent a significant advancement in ocular drug delivery, moving beyond conventional dosing schedules. For instance, Regeneron Pharmaceuticals, Inc. announced in August 2023 that the U. S. Food and Drug Administration approved Eylea HD (aflibercept) Injection 8 mg for the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, allowing for extended dosing intervals of up to 16 weeks following initial monthly doses. This shift towards less frequent administration enhances convenience for patients and streamlines clinical workflows, promising improved long-term visual outcomes.

Segmental Insights

The Eylea segment is experiencing rapid growth within the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, largely due to its established efficacy and robust clinical performance across multiple retinal conditions, including wet age-related macular degeneration and diabetic macular edema. Its widespread adoption is further driven by the convenience offered through longer dosing intervals and formulations like pre-filled syringes, enhancing patient comfort and treatment adherence. Additionally, recent regulatory approvals for advanced formulations, such as the U. S. FDA approval for Eylea HD, underscore its pivotal role in reshaping retinal disease treatment paradigms and significantly contributing to its compelling growth trajectory.

Regional Insights

North America dominates the global anti-vascular endothelial growth factor therapeutics market due to its highly developed healthcare infrastructure and significant prevalence of target ocular diseases, including age-related macular degeneration and diabetic retinopathy. The region benefits from substantial investment in research and development by leading pharmaceutical firms, facilitating early access to innovative therapies. A robust regulatory framework, exemplified by the U. S. Food and Drug Administration's consistent approvals of new anti-VEGF agents, coupled with high patient awareness and comprehensive insurance coverage, collectively underpins North America's prominent market leadership.

Recent Developments

In October 2025, Celltrion, Inc. received approval from the U.S. Food and Drug Administration (FDA) for Eydenzelt (aflibercept-boav), a biosimilar referencing Eylea. Eydenzelt is indicated for the treatment of neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR). This approval, based on analytical, nonclinical, and clinical data, marks Celltrion's entry into the ophthalmology market with a VEGF inhibitor that blocks new blood vessel growth and reduces vascular permeability.

In October 2025, Chinese biopharmaceutical company Hutchmed presented successful Phase III trial data for fruquintinib, an anti-VEGF drug, in combination with Eli Lilly & Innovent Biologics' PD-1 inhibitor, Tyvyt (sintilimab), for renal cell carcinoma. The FRUSCIA-2 study revealed a statistically significant improvement in progression-free survival for patients receiving the combination therapy. This collaboration and breakthrough research highlight a dual-mechanism approach, with fruquintinib functioning as a vascular endothelial growth factor inhibitor, offering a potential new treatment option for advanced renal cell carcinoma.

In December 2024, Roche announced that the European Medicines Agency granted approval for Vabysmo (faricimab) in a 6.0 mg single-dose prefilled syringe format. This new product launch provides an alternative, ready-to-use option for treating neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). The prefilled syringe delivers the same medicine as the previously available Vabysmo vials and represents the first and only prefilled syringe containing a bispecific antibody to treat these retinal conditions in the European Union.

In October 2024, Regeneron announced positive three-year results from an extension study of the Phase 3 PHOTON trial for Eylea HD (aflibercept, 8 mg injection) in patients with diabetic macular oedema. The data, presented at the American Academy of Ophthalmology Annual Meeting, demonstrated that the majority of patients maintained visual and anatomic improvements achieved by the end of the second year. These findings supported longer treatment intervals for Eylea HD patients, indicating sustained efficacy and reduced fluid re-accumulation following initial dosing, a significant breakthrough in anti-VEGF retinal disease management.

Key Market Players

F. Hoffmann-La Roche Ltd.
Biogen MA Inc.
Pfizer Inc.
Coherus BioSciences, Inc.
Amgen Inc.
Viatris Inc.
Bausch Health Companies Inc.
Novartis AG
Regeneron Pharmaceuticals Inc.

By Product	By Disease	By End Users	By Region
Eylea Lucentis Beovu	Macular Edema Diabetic Retinopathy Retinal Vein Occlusion Age-related Macular Degeneration	Hospitals & Clinics Ambulatory Care centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Product:

o Eylea

o Lucentis

o Beovu

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Disease:

o Macular Edema

o Diabetic Retinopathy

o Retinal Vein Occlusion

o Age-related Macular Degeneration

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By End Users:

o Hospitals & Clinics

o Ambulatory Care centers

o Others

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ United Kingdom

§ Italy

§ Germany

§ Spain

o Asia Pacific

§ China

§ India

§ Japan

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market.

Available Customizations:

Global Anti-Vascular Endothelial Growth Factor Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Anti-Vascular Endothelial Growth Factor Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Product (Eylea, Lucentis, Beovu)

5.2.2. By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration)

5.2.3. By End Users (Hospitals & Clinics, Ambulatory Care centers, Others)

5.2.4. By Region

5.2.5. By Company (2024)

5.3. Market Map

6. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Product

6.2.2. By Disease

6.2.3. By End Users

6.2.4. By Country

6.3. North America: Country Analysis

6.3.1. United States Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Product

6.3.1.2.2. By Disease

6.3.1.2.3. By End Users

6.3.2. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Product

6.3.2.2.2. By Disease

6.3.2.2.3. By End Users

6.3.3. Mexico Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Product

6.3.3.2.2. By Disease

6.3.3.2.3. By End Users

7. Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Product

7.2.2. By Disease

7.2.3. By End Users

7.2.4. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Product

7.3.1.2.2. By Disease

7.3.1.2.3. By End Users

7.3.2. France Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Product

7.3.2.2.2. By Disease

7.3.2.2.3. By End Users

7.3.3. United Kingdom Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Product

7.3.3.2.2. By Disease

7.3.3.2.3. By End Users

7.3.4. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Product

7.3.4.2.2. By Disease

7.3.4.2.3. By End Users

7.3.5. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Product

7.3.5.2.2. By Disease

7.3.5.2.3. By End Users

8. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Product

8.2.2. By Disease

8.2.3. By End Users

8.2.4. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Product

8.3.1.2.2. By Disease

8.3.1.2.3. By End Users

8.3.2. India Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Product

8.3.2.2.2. By Disease

8.3.2.2.3. By End Users

8.3.3. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Product

8.3.3.2.2. By Disease

8.3.3.2.3. By End Users

8.3.4. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Product

8.3.4.2.2. By Disease

8.3.4.2.3. By End Users

8.3.5. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Product

8.3.5.2.2. By Disease

8.3.5.2.3. By End Users

9. Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Product

9.2.2. By Disease

9.2.3. By End Users

9.2.4. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Product

9.3.1.2.2. By Disease

9.3.1.2.3. By End Users

9.3.2. UAE Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Product

9.3.2.2.2. By Disease

9.3.2.2.3. By End Users

9.3.3. South Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Product

9.3.3.2.2. By Disease

9.3.3.2.3. By End Users

10. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Product

10.2.2. By Disease

10.2.3. By End Users

10.2.4. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Product

10.3.1.2.2. By Disease

10.3.1.2.3. By End Users

10.3.2. Colombia Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Product

10.3.2.2.2. By Disease

10.3.2.2.3. By End Users

10.3.3. Argentina Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Product

10.3.3.2.2. By Disease

10.3.3.2.3. By End Users

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. F. Hoffmann-La Roche Ltd.

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Biogen MA Inc.

15.3. Pfizer Inc.

15.4. Coherus BioSciences, Inc.

15.5. Amgen Inc.

15.6. Viatris Inc.

15.7. Bausch Health Companies Inc.

15.8. Novartis AG

15.9. Regeneron Pharmaceuticals Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market in 2024?

Which is the dominating region in the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market?

Which is the fastest growing segment in the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market?

What is the expected growth rate of the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market?